Meeting
2023 ASCO Annual Meeting
Heterogeneous baseline immune cell infiltration landscape as a predictor of pathological complete response in locally advanced esophageal squamous cell carcinoma (ESCC) following neoadjuvant chemotherapy and immunotherapy: Results from a single-arm, phase II clinical trial (SEEK-01).
Authors
Guangyu Yao
Zhongshan Hospital, Fudan University, Shanghai, China
Guangyu Yao , Renfeng Wang , Zhiliang Huang , Chaoxiang Du , Borong Chen , Zhenyang Lin , Tao Zhang , Zhonghua Wu , Hong Fan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer - Advanced/Metastatic Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4047)
DOI
10.1200/JCO.2023.41.16_suppl.4047
Abstract #
4047
Poster Bd #
368
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II trial.
First Author: Lei Gong
Poster
2023 ASCO Annual Meeting
Efficacy and safety of camrelizumab combined with chemotherapy versus chemotherapy alone as preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma: Preliminary results from a multicenter, prospective, randomized controlled study.
First Author: Renquan Zhang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A randomized controlled phase III study comparing surgery alone versus adjuvant nivolumab versus adjuvant S-1 for locally advanced esophageal cancer with no pathological complete response: JCOG2206 (SUNRISE Trial).
First Author: Satoru Matsuda
Poster
2023 ASCO Annual Meeting
Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin followed by adjuvant tislelizumab in patients with early triple-negative breast cancer.
First Author: Zefei Jiang